Forest Infasurf
Executive Summary
Marketing of the lung surfactant calfactant will begin in October, following Buffalo federal court ruling that Infasurf does not infringe Abbott's Survanta (beractant) patent. The ruling overturns a lower court decision against Forest in September. Infasurf was approved in July 1998 for respiratory distress syndrome (1"The Pink Sheet" July 13, p. 4)
You may also be interested in...
Dey Curosurf Low Volume Dosing May Be Differentiating Point For Surfactant
Dey may highlight low volume dosing as a way to differentiate its newly approved surfactant product Curosurf from other surfactants.
Dey Curosurf Low Volume Dosing May Be Differentiating Point For Surfactant
Dey may highlight low volume dosing as a way to differentiate its newly approved surfactant product Curosurf from other surfactants.
Forest Celexa On Pace To Exceed $300 Mil.; W-L Nearing Payments
Warner-Lambert expects to begin earning co-promotion income from its marketing efforts for Forest's Celexa (citalopram) in the next quarter.